Myditin (Pridinol Mesilate)

Pridinol mesilate acts on the central nervous system, exhibiting anticholinergic activity that modulates neurotransmitter pathways involved in muscle tone regulation. By reducing reflex hyperexcitability, it promotes skeletal muscle relaxation without directly acting on the muscle fibers.

The dosage of Myditin is individualized and set by the prescribing healthcare professional based on the patient’s condition, age, and response. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for Pridinol mesilate in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against possible risks before prescribing Myditin to pregnant or nursing women. It is generally used only when clearly needed.

To order Myditin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myditin (Pridinol mesilate) belongs to the centrally acting muscle relaxant class and offers anticholinergic properties. Compared with other agents such as baclofen or tizanidine, it may have a different side‑effect profile, particularly a lower risk of muscle weakness but a higher likelihood of anticholinergic effects like dry mouth.

Myditin should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Myditin is taken orally. The tablet (or other oral form) should be swallowed with water, preferably with or after a meal to reduce gastrointestinal irritation, unless otherwise directed by a healthcare professional.

Serious risks, though rare, include cardiac arrhythmias, severe allergic reactions such as anaphylaxis, hepatic dysfunction, and extrapyramidal symptoms. Patients should seek immediate medical attention if they experience chest pain, rash, swelling, difficulty breathing, or abnormal movements.

Myditin is contraindicated in individuals with known hypersensitivity to Pridinol mesilate or any excipients, patients with severe glaucoma, uncontrolled urinary retention, or those taking medications that may cause dangerous additive anticholinergic or CNS depressant effects without medical supervision.